hero image
Dr. Cheryl  Rosen - University Health Network. Toronto, ON, CANADA

Dr. Cheryl Rosen

Head, Division of Dermatology | University Health Network

Toronto, ON, CANADA

A specialist in dermatology in the program of Medical and Community Care

Media

Publications:

Dr. Cheryl  Rosen Publication

Documents:

Photos:

Dr. Cheryl  Rosen Photo Dr. Cheryl  Rosen Photo Dr. Cheryl  Rosen Photo Dr. Cheryl  Rosen Photo

Videos:

Audio/Podcasts:

Biography

Dr. Cheryl Rosen is a dermatologist at Toronto Western Hospital. Dr. Rosen's research interests are in public education for skin cancer prevention, psoriasis and psoriatic arthritis and the effects of ultraviolet radiation on cutaneous biology.

Industry Expertise (4)

Health Care - Services

Research

Health Care - Providers

Health and Wellness

Areas of Expertise (5)

Sun Damage

Skin Protection

Psoriasis and Psoriatic Arthritis

Dermatology

Skin Cancer

Education (4)

Massachusetts General Hospital, Harvard University: Fellowship, Clinical Practice and Research

University of Toronto: Dermatology, Residency

University of Toronto: Internship, Internal Medicine

University of Toronto: MD, Medicine

Affiliations (5)

  • University of Toronto : Associate Professor of Medicine
  • Canadian Dermatology Association : National Director of the Sun Awareness Program
  • Ontario Sun Safety Working Group : Member & Past Chair
  • Group for Research and Assessment of Psoriasis and Psoriatic Arthritis : Member
  • Canadian Institutes of Health Research Network : Member

Media Appearances (5)

Sunscreen: what you need to know

Canadian Dermatology Association  online

2014-05-23

Summer has finally arrived, so it’s definitely time for hats, sunglasses and sunscreen. Have you ever stood in the aisle at the drugstore facing row upon row of sunscreen, not knowing how to choose one from the next? Let’s see if we can make your next purchase a little simpler...

view more

Don't forget the sunscreen

U of T News  online

2013-06-07

Summer: the days are longer and the lakes are warming up but watch out for that sun. It can harm skin and increase the risk of skin cancer. The Canadian Dermatology Association notes that every week, 56 Ontarians are diagnosed with melanoma, a potentially deadly form of skin cancer. This year, the association says there will be an estimated 2,950 new cases of melanoma diagnosed in Ontario and 460 deaths...

view more

5 Sun Safety Tips You Need to Know

UHN  online

2013-02-08

Most Canadians would argue that summers are too short. August is already upon us and with so many fun outdoor activities to take part in, like canoeing, swimming and camping,​ it’s no wonder we wish the season was longer. “The key is to enjoy your summer,” said​ Dr. Cheryl Rosen, Dermatologist, UHN. “But protect yourself as best you can while doing so.” We checked in with Dr. Rosen to learn five tips for protecting yourself against the sun this summer...

view more

Sunless tanning 'Barbie' drug raises concern

The Globe and Mail  online

2011-05-10

Dr. Cheryl Rosen, head of dermatology at Toronto Western Hospital, explains why there is growing concern over the Barbie Drug...

view more

If I Had - An Outdoor Job - Dr. Cheryl Rosen, MD, University of Toronto

InsiderMedicine  online

2008-11-17

Welcome to Insidermedicine's If I Had, where we get a chance to ask an expert what they would do if they had a medical condition. At the recent Annual Conference of the Canadian Dermatology Association in Montreal, we caught up with Dr. Cheryl Rosen, MD, who is a Dermatologist at Toronto Western Hospital and Associate Professor at the University of Toronto. Dr. Rosen is also the National Director of the Sun Awareness Program for the CDA...

view more

Patents (1)

Ampk-related serine/threonine kinase, designated snark

WO 2002012456 A3

2002-09-19

The cloning and function of a new AMPK-related kinase, designated SNARK, are described. The kinase SNARK is involved in the stress response to glucose deprivation. Provided are the rodent and human genes encoding SNARK, and the SNARK protein and useful fragments, in isolated form. Also provided are SNARK expression systems and assays useful to identify SNARK substrates and SNARK activity modulators, and antibodies useful as SNARK modulators for instance in therapeutic applications to modulate the metabolism of glucose.

view more

Articles (5)

Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity


Nature Genetics

2012-01-01

To gain further insight into the genetic architecture of psoriasis, we conducted a meta-analysis of 3 genome-wide association studies (GWAS) and 2 independent data sets genotyped on the Immunochip, including 10,588 cases and 22,806 controls. We identified ...

view more


Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis


Arthritis Care & Research

2011-01-01

To determine whether the presence of psoriatic arthritis (PsA) is associated with greater comorbidity, in particular cardiovascular morbidity, compared to psoriasis without arthritis. Methods Six hundred eleven patients with PsA were recruited from the University ...

view more


Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada


Canadian Medical Association Journal

2010-01-01

We systematically searched the MEDLINE database, for the period 1996 to June 30, 2008, and the Cochrane Library using the terms “vitamin D,”“vitamin D deficiency,”“25-hydroxyvitamin D,”“meta-analysis” and “systematic review.” We identified 168 potentially ...

view more


Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS)


Annals of the Rheumatic Diseases

2009-01-01

To develop and validate a psoriatic arthritis (PsA) screening questionnaire: the Toronto Psoriatic Arthritis Screen (ToPAS). Methods: The ToPAS was developed through review of items seen in patients with PsA and evaluation by patients with PsA and patients ...

view more


Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double-blind, randomized, placebo-controlled clinical trial


Arthritis and Rheumatism

2004-01-01

Current treatment options for psoriatic arthritis (PsA) are limited. Leflunomide, an oral pyrimidine synthesis inhibitor, is highly effective in the treatment of rheumatoid arthritis, and small studies have suggested similar efficacy in PsA. We undertook this double-blind, ...

view more


 Your profile is not published.

Contact